Novasep and Lysogene Team up for Gene Therapy Product
23rd June 2020
Novasep, a French contract services company, has signed an agreement with compatriot biopharma Lysogene to develop and manufacture LYS-GM101, the latter’s adeno-associated virus (AAV)rh10-based gene therapy drug candidate to treat GM1 gangliosidosis, a rare and inherited neuronopathic lysosomal storage disorder that progressively destroys nerve cells in the brain and spinal cord.
Under the agreement, the companies will also consolidate their existing partnership on the development and manufacturing of Lysogene's lead gene therapy product, LYS-SAF302, which is currently in late-phase clinical trials.
Lysogene’s chief technical officer Mark Plavsic said: “By extending our collaboration, we secure the clinical production of our experimental treatment for GM1 gangliosidosis and take an option for a smooth and effective technical transfer to a future commercial process.”
Lysogene is focused on treating orphan diseases of the central nervous system (CNS), including lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial for LYS-SAF203 to treat mucopolysaccharidosis (MPS) type IIIA is currently ongoing with US-based partner Sarepta Therapeutics.
The companies previously signed an exclusive license agreement in October 2018 for LYS-SAF203, under which Sarepta will hold commercial rights to the therapy in the US and in markets outside Europe, while Lysogene will maintain commercial exclusivity in Europe.
For more information visit www.chemanager-online.com/en/